The biotechnology industry is undergoing a profound transformation, fueled in large part by advances in artificial intelligence (AI). AI integration in biotech is speeding up research, improving drug discovery, and improving patient outcomes. AI enables biotech companies to bring new and effective treatments to market faster. Wall Street seems particularly excited about two of these AI-focused clinical-stage biotech companies, with consensus estimates calling for enormous long-term potential. Let’s look at why Wall Street analysts believe that both Acumen Pharmaceuticals (ABOS) and Eledon Phar…